Clovis Oncology Inc  

(Public, NASDAQ:CLVS)   Watch this stock  
Find more results for CLVS
+4.95 (9.01%)
After Hours: 60.20 +0.32 (0.53%)
Feb 22, 5:36PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 58.04 - 60.03
52 week 45.42 - 99.45
Open 58.88
Vol / Avg. 3.58M/1.36M
Mkt cap 2.94B
P/E     -
Div/yield     -
EPS -8.28
Shares 49.01M
Beta 1.05
Inst. own 111%
Feb 26, 2018
Q4 2017 Clovis Oncology Inc Earnings Call - 4:30PM EST - Add to calendar
Feb 26, 2018
Q4 2017 Clovis Oncology Inc Earnings Release - 4:00PM EST - Add to calendar
Jan 9, 2018
Clovis Oncology Inc at JPMorgan Healthcare Conference - Q&A
Jan 9, 2018
Clovis Oncology Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -360.97% -447611.50%
Operating margin -360.15% -477862.80%
EBITD margin - -372706.40%
Return on average assets -29.40% -64.78%
Return on average equity -75.69% -235.10%
Employees 278 -
CDP Score - -


5500 Flatiron Pkwy Unit 100
BOULDER, CO 80301-2834
United States - Map
+1-303-6255000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company's product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFR) 1-3, platelet-derived growth factor receptors (PDGFR) alpha and beta and fibroblast growth factor receptors (FGFR) 1-3. Rociletinib is an oral mutant-selective inhibitor of epidermal growth factor receptor (EGFR).

Officers and directors

M. James E. Barrett Ph.D. Independent Chairman of the Board
Age: 74
Bio & Compensation  - Reuters
Patrick J. Mahaffy President, Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Daniel W. Muehl Senior Vice President of Finance, Principal Accounting Officer and Principal Financial Officer
Age: 54
Bio & Compensation  - Reuters
Gillian C. Ivers-Read Executive Vice President - Technical Operations, Chief Regulatory Officer
Age: 63
Bio & Compensation  - Reuters
Lindsey Rolfe BSc, MB ChB, MRCP, F Executive Vice President - Clinical and Pre-Clinical Development and Pharmacovigilance and Chief Medical Officer
Age: 49
Bio & Compensation  - Reuters
C. Dale Hooks Senior Vice President, Chief Commercial Officer
Age: 50
Bio & Compensation  - Reuters
Brian G. Atwood Independent Director
Age: 64
Bio & Compensation  - Reuters
James C. Blair Ph.D. Independent Director
Age: 77
Bio & Compensation  - Reuters
Keith T. Flaherty M.D. Independent Director
Age: 46
Bio & Compensation  - Reuters
Ginger L. Graham Independent Director
Age: 62
Bio & Compensation  - Reuters